SEC Comment Letter for Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771) (HEPA) — Apr 24, 2025
Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771)
Date: April 24, 2025 · CIK: 0001583771 · Accession: 0000000000-25-004349
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Hepion Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 16, 2025 Dear John Brancaccio:
April 24, 2025
John Brancaccio Interim Chief Executive Officer Hepion Pharmaceuticals, Inc. 55 Madison Ave., Suite 400 - PMB# 4362 Morristown, NJ 07960
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: Jeffrey Fessler, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 24, 2025 John Brancaccio Interim Chief Executive Officer Hepion Pharmaceuticals, Inc. 55 Madison Ave., Suite 400 - PMB# 4362 Morristown, NJ 07960 Re: Hepion Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 16, 2025 Dear John Brancaccio: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Fessler, Esq. </TEXT> </DOCUMENT>